An Alzheimer’s re­jec­tion; Our #JPM23 dis­patch­es; Count Mod­er­na in for RSV; Biotech lay­offs per­sist; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We be­gan the week with an Amer­i­can hol­i­day and now end with an East Asian one. Hap­py Lu­nar New Year to all who cel­e­brate!

An Alzheimer’s re­jec­tion

Just days af­ter wav­ing through Bio­gen and Ei­sai’s Leqem­bi, the FDA squashed ac­cel­er­at­ed hopes for Eli Lil­ly’s Alzheimer’s drug, ask­ing for more da­ta. Lil­ly said reg­u­la­tors de­nied the ac­cel­er­at­ed ap­proval for its an­ti-amy­loid an­ti­body, do­nanemab, “based on lim­it­ed num­ber of pa­tients with 12-month drug ex­po­sure da­ta” in the sub­mis­sion. The com­pa­ny had been plan­ning to file for full ap­proval once it re­ports Phase III da­ta lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER